Kronos Bio Inc (NAS:KRON)
$ 0.94 0.02 (2.17%) Market Cap: 56.72 Mil Enterprise Value: -43.55 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 32/100

Kronos Bio Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 10:20PM GMT
Release Date Price: $3.35 (+2.76%)
Salveen Richter
Goldman Sachs - Analyst

Good afternoon. Thanks so much for joining us. We're really pleased to have the Kronos team here with us. We have Norbert Bischofberger, President and CEO; Yasir Al-Wakeel, CFO; and Jorge DiMartino, CMO and Head of Clinical Development.

Questions & Answers

Salveen Richter
Goldman Sachs - Analyst

So starting here, your CDK9 inhibitor is the first molecule to emerge from your SMM platform. Could you start by walking through the key takeaways from the first data release from KB-0742, as well as the broader implications for the platform as a whole?

Norbert Bischofberger
Kronos Bio, Inc. - President & CEO

Yeah. Thanks, Salveen. Before we start answering the question, I want to thank you and the Goldman Sachs team for having us, hosting us, at this sunny and incredibly nice place here in Southern California.

And the only other comment I would like to make, Salveen, I'm actually very happy with where we are as a company. We have three compounds in clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot